Galectin Therapeutics Inc. (GALT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Galectin Therapeutics Inc. (GALT) Healthcare & Pipeline Overview

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing galectin-3 inhibitors, primarily belapectin, for fibrotic diseases and cancer. Their focus on unmet needs in NASH cirrhosis and other fibrotic conditions positions them within the competitive biotechnology landscape, pending successful clinical trial outcomes.

What Is the Investment Thesis for GALT?

Galectin Therapeutics' investment thesis hinges on the successful completion of its Phase III clinical trial for belapectin in NASH cirrhosis. The potential market for NASH therapies is substantial, driven by the increasing prevalence of obesity and related metabolic disorders. Positive trial results and subsequent regulatory approval could lead to significant revenue generation. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from other companies developing NASH therapies. The company's market capitalization of $235M reflects both the potential upside and the inherent risks in clinical-stage biotechnology companies. Continued development of GM-CT-01 and expansion into other fibrotic indications could provide additional value drivers, but these are further out in the future and carry their own development risks.

Based on FMP financials and quantitative analysis

GALT Key Highlights

Belapectin is in Phase III clinical trials for NASH cirrhosis, a significant unmet medical need.

• GM-CT-01 is in pre-clinical development for cardiac and vascular fibrosis, expanding the pipeline.
• The company has a collaborative joint venture, Galectin Sciences, LLC, focused on oral galectin-3 inhibitors.
• Galectin Therapeutics is exploring the potential of belapectin in treating psoriasis, lung fibrosis, and kidney fibrosis.
• The company's market capitalization is $0.17 billion, reflecting its clinical-stage status and potential upside.

Who Are GALT's Competitors?

GALT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GALT's Key Strengths?

Lead product candidate, belapectin, in Phase III clinical trials.

• Proprietary galectin-3 inhibitor technology.
• Focus on unmet medical needs in fibrotic diseases and cancer.
• Experienced management team.

What Are GALT's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on the success of belapectin.
• Limited financial resources.
• Small number of employees.

What Could Drive GALT Stock Higher?

Results from the Phase III clinical trial of belapectin for NASH cirrhosis.

• Development of GM-CT-01 for cardiac and vascular fibrosis.
• Research and development of oral galectin-3 inhibitors.
• Exploration of belapectin in treating psoriasis, lung fibrosis, and kidney fibrosis.

What Are the Key Risks for GALT?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Failure of the Phase III clinical trial for belapectin.
• Regulatory delays or rejection of belapectin.
• Competition from other companies developing NASH therapies.
• Dependence on securing additional funding to support operations.
• Patent challenges to the company's intellectual property.

What Are the Growth Opportunities for GALT?

• Successful completion of the Phase III clinical trial for belapectin in NASH cirrhosis and subsequent regulatory approval would allow Galectin Therapeutics to capture a significant share of this market. The timeline for potential market entry depends on the clinical trial results and regulatory review process, but could be within the next 2-3 years.
• Development of GM-CT-01 for cardiac and vascular fibrosis: The development of GM-CT-01 for cardiac and vascular fibrosis represents another growth opportunity for Galectin Therapeutics. The market for therapies targeting cardiac and vascular fibrosis is also substantial, driven by the aging population and the increasing prevalence of cardiovascular diseases. Pre-clinical development is ongoing, and the timeline for potential clinical trials is uncertain.
• Expansion into other fibrotic indications: Galectin Therapeutics is exploring the potential of belapectin in treating psoriasis, lung fibrosis, and kidney fibrosis. These indications represent additional growth opportunities for the company. The timelines for development in these indications are uncertain, but could provide long-term growth potential.
• Partnerships and collaborations: Galectin Therapeutics could pursue partnerships and collaborations with other companies to accelerate the development and commercialization of its product candidates. This could provide access to additional resources and expertise, and could help to mitigate the risks associated with drug development. The timing and nature of any potential partnerships are uncertain.
• Oral galectin-3 inhibitors: Through its collaborative joint venture, Galectin Sciences, LLC, Galectin Therapeutics is engaged in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. This could provide a more convenient and patient-friendly treatment option compared to injectable therapies like belapectin. The timeline for development of oral galectin-3 inhibitors is uncertain, but could provide long-term growth potential.

What Are GALT's Competitive Advantages?

• Proprietary galectin-3 inhibitor technology.
• Belapectin in Phase III clinical trials, providing a potential first-mover advantage in the NASH cirrhosis market.
• Intellectual property protection for product candidates.
• Expertise in galectin biology and drug development.

What Does GALT Do?

Galectin Therapeutics Inc., founded in 2000 and based in Norcross, Georgia, is a clinical-stage biopharmaceutical company dedicated to the research and development of therapies for fibrotic, cancer, and other diseases. Originally named Pro-Pharmaceuticals, Inc., the company rebranded to Galectin Therapeutics, Inc. in May 2011 to reflect its strategic focus on galectin-3 and its role in various disease processes. The company's lead product candidate, belapectin (GR-MD-02), is a galectin-3 inhibitor currently in Phase III clinical trials for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis. Belapectin is a galactoarabino-rhamnogalacturonan polysaccharide polymer designed to bind to galectin-3, a protein implicated in fibrosis and cancer progression. In addition to belapectin, Galectin Therapeutics is also developing GM-CT-01 for the treatment of cardiac and vascular fibrosis, currently in the pre-clinical development stage. The company is also exploring the potential of belapectin in treating psoriasis, lung fibrosis, and kidney fibrosis. Through its collaborative joint venture, Galectin Sciences, LLC, co-owned with SBH Sciences, Inc., the company is engaged in the research and development of small organic molecule inhibitors of galectin-3 for oral administration, expanding its therapeutic approach to targeting galectin-3.

What Products and Services Does GALT Offer?

• Develop therapies for fibrotic diseases.
• Develop therapies for cancer.
• Focus on galectin-3 inhibitors.
• Conduct Phase III clinical trials for belapectin in NASH cirrhosis.
• Develop GM-CT-01 for cardiac and vascular fibrosis.
• Research belapectin for psoriasis, lung fibrosis, and kidney fibrosis.

How Does GALT Make Money?

• Research and development of novel therapies.
• Clinical trials to evaluate the safety and efficacy of product candidates.
• Seeking regulatory approval for product candidates.
• Potential commercialization of approved products, or licensing to other companies.

What Industry Does GALT Operate In?

Galectin Therapeutics operates in the biotechnology industry, which is characterized by high risk and high reward. The market for NASH therapies is projected to grow significantly in the coming years, driven by the increasing prevalence of the disease. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms developing various approaches to treating NASH, including FXR agonists, PPAR agonists, and ASK1 inhibitors. Galectin Therapeutics' galectin-3 inhibitor approach represents a novel mechanism of action and could offer a differentiated therapeutic option if successful.

Who Are GALT's Key Customers?

• Patients with liver fibrosis associated with fatty liver disease and NASH cirrhosis.
• Patients with cardiac and vascular fibrosis.
• Potentially patients with psoriasis, lung fibrosis, and kidney fibrosis in the future.
• Potential pharmaceutical partners for licensing or collaboration agreements.

Company Profile

Galectin Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Norcross, US. The company is led by CEO Joel Lewis. GALT has traded publicly since 2002.

Galectin Therapeutics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for Galectin Therapeutics Inc. stands at 21.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.6%, the inverse of the P/E and a quick read on earnings relative to price.

GALT Valuation & Market Position

With a $235M market cap, Galectin Therapeutics Inc. sits in the micro-cap segment of the market. Relative to its peer group, GALT's quantitative score of 28/100 is below the peer average of 64/100.

Galectin Therapeutics Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 5.7% below estimates on average.

Wall Street analysts project Galectin Therapeutics Inc. revenue of about $179.7M for fiscal 2026, with EPS near $-0.30.

GALT Financials

GALT Latest News

GALT Analyst Consensus

GALT MoonshotScore

Common Questions About GALT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources